Prime MedicinePRME +8.45%25 5-Year RORE % is -5.23 as of Mar. 2026. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 5 warning signs investors should review. Among 1,138 Biotechnology companies, Prime Medicine ranks better than 58.88% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Prime Medicine's 5-Year RORE % for the quarter that ended in Mar. 2026 was -5.23%.
The industry rank for Prime Medicine's 5-Year RORE % or its related term are showing as below:
PRME's 5-Year RORE % is ranked better than 58.88% of 1138
companies
in the Biotechnology industry
Industry Median: -10.67
vs PRME: -5.23
Prime Medicine (NAS:PRME) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Prime Medicine 5-Year RORE % Related Terms
Prime Medicine 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Prime Medicine's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRME vs EIKN, CRMD, STTK: 5-Year RORE % Comparison
For the Biotechnology subindustry, Prime Medicine's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prime Medicine 5-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prime Medicine's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Prime Medicine's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.
Prime Medicine (PRME) has a 5-Year RORE % of -5.23 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Prime Medicine and its competitors. According to the industry distribution chart, Prime Medicine ranks #468 out of 1138 companies in the Biotechnology industry, placing it in the top 41.1%.
Is Prime Medicine's 5-Year RORE % too high?
Prime Medicine's current 5-Year RORE % is -5.23. Based on the distribution chart, Prime Medicine ranks #468 out of 1138 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's 5-Year RORE % compare to EIKN and CRMD?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #468 out of 1138 companies for 5-Year RORE %. This puts Prime Medicine in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Biotechnology company?
A good 5-Year RORE % depends on the Biotechnology industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Prime Medicine and its competitors. Prime Medicine's current 5-Year RORE % is -5.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current 5-Year RORE % of -5.23. The current 5-Year RORE % is -5.23. Prime Medicine's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Prime Medicine (PRME), the current 5-Year RORE % is -5.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score
Get the complete analysis for PRME
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRME has been successfully added to your 
